Bristol-Myers Squibb is set to buy peer Celgene in a cash-and-stock deal that will bring together two healthcare corporate venturing portfolios.
Bristol-Myers Squibb (BMS) agreed yesterday to acquire another US-listed pharmaceutical company with corporate venturing assets, Celgene, in a cash-and-share deal that will create a $74bn firm.
BMS will take 69% of the combined company’s shares while Celgene will get the remaining 31%, with the transaction expected to close in March this year.
The deal is expected to create a firm with a particularly strong presence in oncology, haematology, cardiovascular activities, immunology and inflammation, but it is so far unclear what…
